Eckert & Ziegler SEXTER:EUZ -1.03%98 EBITDA Margin % is 28.34% as of Mar. 2026, which is 16% above its 10-year median of 24.39. GuruFocus rates XTER:EUZ with a GF Score™ of 98/100 and a GF Value™ of €16.25 (Fairly Valued). Among 816 Medical Devices & Instruments companies, Eckert & Ziegler SE ranks better than 91.18% on this metric.
Eckert & Ziegler SE (XTER:EUZ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Eckert & Ziegler SE EBITDA Margin % Related Terms
Eckert & Ziegler SE EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Eckert & Ziegler SE's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:EUZ vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eckert & Ziegler SE (XTER:EUZ) has a EBITDA Margin % of 28.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eckert & Ziegler SE and its competitors. This is 16% above median its historical median of 24.39. Over the past decade, Eckert & Ziegler SE's EBITDA Margin % has ranged from 19.05 to 31.69. According to the industry distribution chart, Eckert & Ziegler SE ranks #72 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 8.8%.
Is Eckert & Ziegler SE's EBITDA Margin % too high?
Eckert & Ziegler SE's current EBITDA Margin % of 28.34% is 16% above median its 10-year median of 24.39. Over the past 10 years, this metric has ranged from a low of 19.05 to a high of 31.69. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Eckert & Ziegler SE's value of 28.34% is 279.1% above this industry median. Based on the distribution chart, Eckert & Ziegler SE ranks #72 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eckert & Ziegler SE ranks #72 out of 816 companies for EBITDA Margin %. This places Eckert & Ziegler SE in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Eckert & Ziegler SE's value of 28.34% is 279.1% above this benchmark. Historically, Eckert & Ziegler SE's own EBITDA Margin % has ranged from 19.05 to 31.69 over the past decade. While the company's 10-year median is 24.39 vs. the industry median of 7.48, Eckert & Ziegler SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current EBITDA Margin % of 28.34% is 279.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current EBITDA Margin % is 28.34%, which is 16% above median its own 10-year median of 24.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (XTER:EUZ) is currently considered Fairly Valued. The stock's GF Value™ is €16.25, compared to a current price of €15.41 — trading 5.2% below its estimated fair value. The current EBITDA Margin % is 28.34%, which is 16% above median its 10-year median of 24.39 and 279.1% above the Medical Devices & Instruments industry median of 7.48. Eckert & Ziegler SE's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Eckert & Ziegler SE (XTER:EUZ), the current EBITDA Margin % is 28.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (XTER:EUZ) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.41 is trading 5.2% below its estimated GF Value™ of €16.25.
GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.
Key valuation signals for XTER:EUZ:
EBITDA Margin %: 28.34% (16% above median its 10-year median of 24.39)
GF Value™: €16.25 vs. price of €15.41 (5.2% below fair value)
Industry Position: 279.1% above the Medical Devices & Instruments median (#72 of 816)
No single metric tells the full story. See the XTER:EUZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score
Get the complete analysis for XTER:EUZ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:EUZ has been successfully added to your 
